| Deal value | $125M |
|---|---|
| Share of market cap | 93.2% |
| Share of annual revenue | 378.5% |
Key highlights
- Total consideration includes $105 million in cash at closing and $20 million in deferred payments
- MaxCyte will issue approximately 20.6 million shares of common stock to the sellers
- The acquisition is expected to nearly double MaxCyte's current annual revenue upon integration
- Full-year 2026 revenue guidance was raised to at least $34.5 million following the announcement
- The deal is projected to close before the end of 2026 subject to regulatory approvals
What Is the Deal?
MaxCyte, Inc. has entered into a definitive securities purchase agreement to acquire all outstanding equity interests of Akron BioProducts LLC from affiliates of Arcline Investment Management. The acquisition involves an upfront cash payment of $105 million, approximately 20.6 million shares of MaxCyte common stock, and $20 million in guaranteed deferred cash. Akron BioProducts is a prominent supplier of GMP-grade reagents and ancillary materials, which are critical components in the manufacturing of next-generation cell therapeutics. The transaction is scheduled to close by the end of 2026, pending customary closing conditions and regulatory clearance under the Hart-Scott-Rodino Act.
Deal Structure & Terms
- Cash component consists of $105 million due at closing, subject to customary working capital adjustments
- Deferred cash payments of $10 million each are scheduled for the first business days of 2028 and 2029
- Stock consideration involves 20,639,733 shares of MXCT common stock issued to the sellers
- A six-month lock-up period will apply to the shares issued as part of the transaction
- MaxCyte obtained a conditional binder for representations and warranties insurance for post-closing recourse
Strategic Rationale
“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”
Financial Context
The acquisition arrives as MaxCyte reports strong operational momentum, with third-quarter 2026 revenue reaching $10.2 million, a 49% increase compared to the prior year. The company core business revenue grew 27% to $8.2 million, while Strategic Platform License revenue contributed $2.0 million. By acquiring Akron, MaxCyte expects to nearly double its annual revenue profile. The $125 million deal value is significant relative to MaxCyte current market capitalization of approximately $134.2 million. Following the deal announcement, the company raised its full-year 2026 revenue guidance to at least $34.5 million, anticipating a return to sustained full-year growth.
Down 9.2% since our story on 10 Nov: $1.30 when we broke it → $1.18 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $1.30 |
|---|---|
| 20 Oct | $1.43 |
| 21 Oct | $1.47 |
| 22 Oct | $1.43 |
| 23 Oct | $1.40 |
| 26 Oct | $1.51 |
| 27 Oct | $1.54 |
| 28 Oct | $1.71 |
| 29 Oct | $1.73 |
| 30 Oct | $1.59 |
| 2 Nov | $1.45 |
| 3 Nov | $1.46 |
| 4 Nov | $1.39 |
| 5 Nov | $1.31 |
| 6 Nov | $1.26 |
| 9 Nov | $1.30 |
| 10 Nov | $1.13 |
| 11 Nov | $1.10 |
| 12 Nov | $1.19 |
| 13 Nov | $1.19 |
| 16 Nov | $1.18 |
Industry Landscape
The cell therapy sector is increasingly focused on vertical integration to secure the supply chain for critical raw materials. GMP-grade reagents, such as those supplied by Akron BioProducts, are essential for maintaining the safety and efficacy of therapeutic products during the scale-up process. As cell therapy developers move toward late-stage clinical trials and commercialization, demand for high-quality ancillary materials has intensified. This acquisition positions MaxCyte as a comprehensive solutions provider, moving beyond its core electroporation technology to offer a broader suite of products required for the entire cell therapy manufacturing lifecycle.
Management commentary
“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”
| Share price | $1.30 |
|---|---|
| Market cap | $134M |
| Revenue (annual) | $33M |
| 1-month price change | +27.45% |
| Sector | HealthcareMedical Devices |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by MaxCyte, Inc. announcing the acquisition of Akron BioProducts LLC.
Track MAXCYTE, INC. live
Get the next MAXCYTE, INC. SEC filing seconds after it lands.



